Risperidone (Risperdal Consta)

A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.

Also Known As:

Networked: 3594 relevant articles (534 outcomes, 1102 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Lieberman, Jeffrey A: 34 articles (10/2015 - 02/2002)
2.	Kane, John M: 31 articles (11/2015 - 01/2003)
3.	Bossie, Cynthia A: 31 articles (07/2014 - 06/2004)
4.	Akhondzadeh, Shahin: 30 articles (09/2015 - 10/2006)
5.	Citrome, Leslie: 28 articles (01/2015 - 02/2002)
6.	Aman, Michael G: 27 articles (04/2015 - 08/2002)
7.	McDougle, Christopher J: 25 articles (11/2015 - 08/2002)
8.	Vitiello, Benedetto: 24 articles (12/2015 - 08/2002)
9.	McEvoy, Joseph P: 23 articles (05/2013 - 02/2002)
10.	Arnold, L Eugene: 22 articles (11/2015 - 08/2002)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 06/01/2004 - "Most patients considered the treatment at least "acceptable" during the study, and mean change at study end corresponded to between "acceptable" and "quite acceptable." After 1 year of risperidone treatment in a naturalistic setting reflecting usual UK clinical practice, patients with chronic schizophrenia showed improvement in symptoms and reduction in disease severity, and only 10 of 79 had relapse; 48.1% of patients were considered to be sustained treatment successes, 36.7% as treatment failures, and 15.2% as not "evaluable." Fifty-one percent of patients were considered to be study successes and 49% as study failures." 08/01/2001 - "Most male (77%) and female (78%) participants were considered to be PANSS responders: risperidone was effective against both the positive and negative symptoms of schizophrenia. " 10/01/2005 - "Risperidone therapy at the earliest possible stage shows optimal improvement in schizophrenia." 06/01/2000 - "Risperidone is a benzisoxazole derivative which has proven efficacy against the positive and negative symptoms of schizophrenia. " 06/01/1998 - "Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia. "
2.	Bipolar Disorder (Mania) 02/01/2010 - "The combination of risperidone with mood stabilizers significantly improved the scores on the Young Mania Rating Scale (YMRS), 17-item Hamilton Rating Scale for Depression (HAMD), 18-item Brief Psychiatric Rating Scale (BPRS), Global Assessment Scale (GAS), and Clinical Global Impression Scale for use in bipolar illness Severity (CGI-BP) at 24 weeks (P < 0.0001). " 02/01/2008 - "Although both hyperactive/impulsive (-7.5 +/- 5.5.6, p < 0.05) and inattentive (-6.8 +/- 5.0, p < 0.05) ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6) showed a 30% reduction in ADHD rating scale scores and had a CGI-I </= 2. These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder." 01/01/2005 - "At week 3, mean Young Mania Rating Scale (YMRS) score reductions from baseline were significantly greater in patients receiving risperidone than placebo (p<0.001). " 06/01/2004 - "Improvement in mean Young Mania Rating Scale total score (adjusted for covariates) was significantly greater in the risperidone than in the placebo group at endpoint (mean change=-10.6 [SD=9.5] versus -4.8 [SD=9.5], respectively), with significant between-group differences seen as early as 3 days after start of treatment (change with risperidone: mean=-6.8 [SD=5.8]; change with placebo: mean=-4.0 [SD=5.8]) and continuing throughout all time points. " 05/01/2004 - "At double-blind endpoint, mean reductions in Young Mania Rating Scale (YMRS) scores were significantly greater in patients receiving risperidone plus mood stabilizer than in those receiving placebo plus mood stabilizer (-14.3 vs. -8.2, p <.001). "
3.	Psychotic Disorders (Schizoaffective Disorder) 04/01/1999 - "The overall positive experience with risperidone has resulted in the drug being widely recommended as a first line treatment option for psychoses." 01/01/1998 - "Scientifically more rigorous prospective studies for the indications and efficacy of risperidone in late onset psychotic disorders and psychoses and behavior syndromes associated with dementing illness are overdue." 09/01/2005 - "Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. " 04/01/2002 - "At low doses, risperidone is an effective and well-tolerated treatment for psychoses in elderly patients that improves the quality of life for both patients and their caregivers." 08/01/2001 - "Despite the limitations of the open-label design, the results indicate that risperidone is a safe and effective therapy in combination with mood-stabilizers for the treatment of patients with manic, hypomanic, and depressive symptoms of mixed episodes in schizoaffective disorder, bipolar type."
4.	Dementia (Dementias) 10/09/2003 - "Risperidone was highly effective and well tolerated in the treatment of behavioural disturbances in dementia under routine conditions of general practice." 03/01/2005 - "In this study of community-based patients with dementia, risperidone significantly improved behavioral and psychological symptoms and, as a result, also reduced caregiver burden. " 02/01/2003 - "Treatment with low-dose (mean = 0.95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." 02/01/1999 - "Risperidone significantly improved symptoms of psychosis and aggressive behavior in patients with severe dementia. " 01/01/2001 - "Numerous open-label and, more recently, placebo-controlled trials have documented the efficacy of risperidone in the management of behavioral and psychological symptoms of dementia. "
5.	Autistic Disorder (Autism) 10/01/2010 - "Our results confirm that risperidone therapy was very effective in reducing some autism symptoms and caused few serious adverse effects. " 08/01/2002 - "The efficacy of risperidone in the treatment of very young children with autistic disorder reported here is consistent with findings in the limited number of cases previously reported in the literature. " 02/01/2007 - "Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism." 01/01/2007 - "Risperidone can be beneficial in some features of autism. " 06/01/2006 - "Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated."

Related Drugs and Biologics

1.	olanzapine (Zyprexa)
2.	Antipsychotic Agents (Antipsychotics)
3.	Haloperidol (Haldol)
4.	quetiapine (Seroquel)
5.	aripiprazole (Abilify)
6.	Clozapine (Clozaril)
7.	ziprasidone (Geodon)
8.	Valproic Acid (Valproate, Semisodium)
9.	Lithium
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Injections
2.	Drug Therapy (Chemotherapy)
3.	Microspheres (Microsphere)
4.	Aftercare (After-Treatment)
5.	Patient Readmission